公开(公告)号：US10273234B2

公开(公告)日：2019-04-30

申请号：US14420020

申请日：2013-08-05

Applicant: BIOGEN MA INC.

Inventor： Kevin Guckian ,  Gnanasambandam Kumaravel ,  Bin Ma ,  Lihong Sun ,  Zhili Xin ,  Lei Zhang

IPC: C07D471/08 ,  A61K31/122 ,  C07C229/48 ,  C07D223/06 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D211/62 ,  A61K45/06 ,  A61K31/397 ,  A61K31/403 ,  A61K31/44 ,  A61K31/55 ,  A61K31/196 ,  A61K31/40 ,  A61K31/439 ,  A61K31/445 ,  C07C211/38 ,  C07D207/08

Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

公开(公告)号：US20190060398A1

公开(公告)日：2019-02-28

申请号：US15918044

申请日：2018-03-12

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  John McCoy

IPC: A61K38/17 ,  C07K16/18 ,  A61K39/395 ,  C07K14/47 ,  C07K14/705 ,  A61K31/70 ,  C12N5/079 ,  A61K38/00 ,  A61K48/00

Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.

公开(公告)号：US20190046456A1

公开(公告)日：2019-02-14

申请号：US16076849

申请日：2017-02-08

Applicant: BIOGEN MA INC.

Inventor： Shyam B. Karki ,  Peter Zawaneh ,  Cheuk-Yui Leung ,  Kalyan Vasudevan ,  Yiqing Lin ,  Jin Xu ,  Andrea Trementozzi ,  Ivan Nestorov

IPC: A61K9/50 ,  A61K31/225 ,  A61K9/48

Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.

公开(公告)号：US20190040384A1

公开(公告)日：2019-02-07

申请号：US15907970

申请日：2018-02-28

Applicant: Biogen MA Inc.

Inventor： C. Frank Bennett ,  Gene Hung ,  Frank Rigo

IPC: C12N15/113 ,  A61K38/30 ,  A61B5/04 ,  A61B5/0488 ,  A61K9/00 ,  A61K31/185 ,  A61K31/7088 ,  A61K35/545 ,  A61K45/06 ,  A61K47/46 ,  A61K48/00 ,  G01N33/50 ,  C12Q1/6883

Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.

公开(公告)号：US20190008817A1

公开(公告)日：2019-01-10

申请号：US16043641

申请日：2018-07-24

Applicant: Biogen MA Inc.

Inventor： Mark Novas ,  Rui (Ray) Zhang

IPC: A61K31/225 ,  G09B19/00 ,  G01N33/49 ,  A61K9/48 ,  A61K9/28 ,  A61K9/00 ,  A61K47/54

Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.

公开(公告)号：US10144732B2

公开(公告)日：2018-12-04

申请号：US15316534

申请日：2015-06-05

Applicant: BIOGEN MA INC.

Inventor： Gnanasambandam Kumaravel ,  Hairuo Peng ,  Zhili Xin

IPC: C07D471/04 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).

公开(公告)号：US20180297992A1

公开(公告)日：2018-10-18

申请号：US15952505

申请日：2018-04-13

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Robin Prince ,  Isaac Marx ,  Joseph P. Lyssikatos ,  Fengmei Zheng ,  Matthew Peterson ,  Daniel B. Patience

IPC: C07D417/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  A61P43/00

CPC classification number: C07D417/14 ,  A61K31/44 ,  A61K31/443 ,  A61K31/506 ,  A61P43/00 ,  C07B2200/13 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US20180273605A1

公开(公告)日：2018-09-27

申请号：US15595733

申请日：2017-05-15

Applicant: Biogen MA Inc. ,  Topotarget Switzerland SA

Inventor： Jeffrey Browning ,  Christine Ambrose ,  Fabienne MacKay ,  Jurg Tschopp ,  Pascal Schneider ,  Jeffrey Thompson

IPC: C07K14/715 ,  A61K38/17 ,  C07K14/705 ,  C07K16/24 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K14/7151 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K2039/505 ,  C07K14/70575 ,  C07K16/241 ,  C07K2319/00

Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

公开(公告)号：US10081619B2

公开(公告)日：2018-09-25

申请号：US15699857

申请日：2017-09-08

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Timothy Raymond Chan ,  Lihong Sun ,  Lei Zhang ,  Gnanasambandam Kumaravel ,  Joseph P. Lyssikatos ,  Kevin Koch ,  Hua Miao

IPC: C07D403/12 ,  C07D487/04 ,  C07D401/14 ,  C07D413/14 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D513/04

CPC classification number: C07D403/12 ,  A61K31/506 ,  C07D239/30 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04 ,  C07F5/027

Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

公开(公告)号：US20180263906A1

公开(公告)日：2018-09-20

申请号：US15988578

申请日：2018-05-24

Applicant: Biogen MA Inc.

Inventor： Matvey E. Lukashev ,  Gilmore O'Neill

IPC: A61K9/00 ,  A61K9/48 ,  G01N33/50 ,  A61K31/7076 ,  A61K31/4704 ,  A61K31/277 ,  A61K31/197 ,  A61K31/194 ,  A61K31/137 ,  A61K31/436 ,  A61K45/06 ,  A61K38/21 ,  A61K9/28 ,  A61K31/225

CPC classification number: A61K9/0065 ,  A61K9/28 ,  A61K9/4891 ,  A61K31/137 ,  A61K31/194 ,  A61K31/197 ,  A61K31/225 ,  A61K31/277 ,  A61K31/436 ,  A61K31/4704 ,  A61K31/7076 ,  A61K38/217 ,  A61K45/06 ,  A61K2300/00 ,  G01N33/502 ,  G01N33/5041 ,  G01N2333/90209 ,  G01N2800/285

Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.